Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician

Figures & data

Table 1 Contraindications and Routes of Administration for the Use of Biologics in Enteric Disease

Biologic	Enteric Disease	Route of Administration	Contraindication/Safety
Infliximab (+Biosimilars)	• Crohn’s Disease Ulcerative Colitis (including ASUC) • *Microscopic colitis • *Celiac Disease (case reports)	• Intravenous • Subcutaneous	• Congestive heart failure • Multiple sclerosis • Malignancies (melanoma, lymphoma) Infections (tuberculosis, hepatitis B reactivation, opportunistic)
Adalimumab	• Ulcerative Colitis  + Crohn's disease	• Subcutaneous
Golimumab	• Ulcerative Colitis	• Subcutaneous
Certolizumab	• Crohn's Disease	• Subcutaneous
Vedolizumab	• Ulcerative Colitis  +Crohn's disease	• Intravenous • Subcutaneous (Europe, Canada only)	• No black box warnings
Natalizumab	• Crohn's Disease	• Intravenous	• Progressive Multifocal Leukoencephalopathy
Ustekinumab	• Ulcerative Colitis  +Crohn's disease • *Microscopic Colitis	• Intravenous (induction) • Subcutaneous	• No black box warnings • Caution: Infections (tuberculosis)
Bezlotoxumab	• C. diff infection	• Intravenous	• No black box warnings • Caution: Congestive heart failure
Dupilumab	• Eosinophilic Esophagitis	• Subcutaneous	• No black box warnings • Ocular surface disorders